EDGAR·FLOW

Scienture Holdings, Inc. — Form 8-K

Filed November 19, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 72/100
What the filing says
Scienture Holdings (market cap ~$10.2M) reported Q3 2026 revenue of $1.25M, up 265% sequentially from $344K in Q2 and 113% YoY from $590K in Q3 2025. REZENOPY (naloxone nasal spray) launched in August 2026 and generated ~$925K in Q3 net product revenue; Arbli (losartan suspension) contributed ~$330K. The company achieved Q3 gross profit of $1.02M (81.3% margin) and narrowed 9-month net loss to $12.2M from $13.4M YoY. Cash position improved to $7.8M (including $3M restricted cash) from $6.7M at year-end 2025. Management expects breakeven operating income and profitability in 2027 based on current sales trajectory.
Why this rating

High-growth commercial inflection (265% sequential, 113% YoY) on micro-cap; two FDA products now generating meaningful revenue materially changes trajectory. Loss narrowing + path to 2027 profitability credible. Relative to $10.2M market cap, $1.25M quarterly revenue is substantial, though execution risk remains material.

Tradability signal
NO TRADE

No trade: positive news with only -1.0% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.33% over 4 hrs, n=592). (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
before filing · preread
$2.46 ▲ 1.03%
at our read · unknown
$2.44
+10 min · unknown
$2.44 ▲ 0.00%
+30 min · unknown
$2.37 ▼ 2.67%
+1 hr · unknown
$2.33 ▼ 4.52%
+4 hrs · unknown
$2.13 ▼ 12.73%

The stock had already moved -1.02% between hitting EDGAR and our read finishing — deltas above are measured from our read.

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ SCNX · stock on Yahoo Finance ↗

See more from November 19, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.